Two proposed Alzheimer’s drugs have failed in clinical trials
The conventional medical treatment of Alzheimer’s disease is very underwhelming. Drugs used for the condition are mostly ineffective. Two new drugs that seemed promising have failed to produce results in clinical trials and have been scrapped.
The drugs are monoclonal antibodies, and are called solanezumab and bapineuzumab.
They were supposed to promote the removal of beta-amyloid deposits in the brain, which are the plaques associated with Alzheimer's disease. Unfortunately neither of the drugs was effective in slowing the loss of cognitive function in patients with mild to moderate Alzheimer's disease.
It is very difficult to reverse Alzheimer’s disease or to stop it in its tracks once it is moderate to advanced. It is much easier to prevent the disease. Unfortunately no one thinks about Alzheimer’s disease until they already have it. It’s one of those conditions that seem way off in the future and that “may never happen to me”
Alzheimer’s related changes to the brain usually begin in a person’s 40s. Start now to protect your brain from harm and nourish it with the right nutrients necessary for healthy cognition. If you are serious about protecting your brain, you will want to know the strategies I’ve outlined in my book Alzheimer’s: 'What you Must Know to protect your Brain'.